Peptide-YY3-36/glucagon-like peptide-1 combination treatment of obese diabetic mice improves insulin sensitivity associated with recovered pancreatic β-cell function and synergistic activation of discrete hypothalamic and brainstem neuronal circuitries

Peptide-YY3-36/glucagon-like peptide-1 combination treatment of obese diabetic mice improves insulin sensitivity associated with recovered pancreatic β-cell function and synergistic activation of discrete hypothalamic and brainstem neuronal circuitries

Objective: Obesity-linked type 2 diabetes (T2D) is a worldwide health concern and many novel approaches are being considered for its treatment and subsequent prevention of serious comorbidities. Co-administration of glucagon like peptide 1 (GLP-1) and peptide YY3-36 (PYY3-36) renders a synergistic d...

Full description

Bibliographic Details
Main Authors: Brandon B. Boland, Rhianna C. Laker, Siobhan O'Brien, Sadichha Sitaula, Isabelle Sermadiras, Jens Christian Nielsen, Pernille Barkholt, Urmas Roostalu, Jacob Hecksher-Sørensen, Sara Rubek Sejthen, Ditte Dencker Thorbek, Arthur Suckow, Nicole Burmeister, Stephanie Oldham, Sarah Will, Victor G. Howard, Benji M. Gill, Philip Newton, Jacqueline Naylor, David C. Hornigold, Jotham Austin, Louise Lantier, Owen P. McGuinness, James L. Trevaskis, Joseph S. Grimsby, Christopher J. Rhodes
Format: Article
Language:English
Published: Elsevier 2022-01-01
Series:Molecular Metabolism
Subjects:
Diabetes
Obesity
Insulin sensitivity
Pancreatic β-cell
Hypothalamus
Glucagon-like peptide-1 (GLP-1)
Online Access:http://www.sciencedirect.com/science/article/pii/S2212877821002477

Internet

http://www.sciencedirect.com/science/article/pii/S2212877821002477

Similar Items